{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:24:12Z","timestamp":1776421452111,"version":"3.51.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40744-025-00776-4","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:07:05Z","timestamp":1751699225000},"page":"873-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase\u00a02 Psoriatic Arthritis Study: A Post Hoc Analysis"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03881059","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslawa","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June Y.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.","journal-title":"Nat Rev Dis Primers"},{"key":"776_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"776_CR3","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1093\/rheumatology\/keab905","volume":"61","author":"P Nash","year":"2022","unstructured":"Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022;61:3257\u201368.","journal-title":"Rheumatology (Oxford)"},{"key":"776_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3899\/jrheum.200124","volume":"96","author":"LC Coates","year":"2020","unstructured":"Coates LC, Merola JF, Grieb SM, Mease PJ, Callis DK. Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2020;96:31\u20135.","journal-title":"J Rheumatol Suppl"},{"key":"776_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"776_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706\u201319.","journal-title":"Ann Rheum Dis"},{"key":"776_CR7","doi-asserted-by":"publisher","first-page":"1759720x2210923","DOI":"10.1177\/1759720X221092376","volume":"14","author":"R Felten","year":"2022","unstructured":"Felten R, Lambert De Cursay G, Lespessailles E. Is there still a place for methotrexate in severe psoriatic arthritis? Ther Adv Musculoskelet Dis. 2022;14:1759720x221092376.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"776_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase\u00a03 trial. J Am Acad Dermatol. 2023;88:40\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"776_CR10","unstructured":"Sotyktu [package insert]. Bristol Myers Squibb, Princeton, NJ, USA; 2022."},{"key":"776_CR11","unstructured":"Sotyktu [product monograph]. Bristol Myers Squibb Canada Co., Montreal, QC, Canada; 2022."},{"key":"776_CR12","unstructured":"Sotyktu [package insert]. Bristol Myers Squibb K.K., Tokyo, Japan; 2022."},{"key":"776_CR13","doi-asserted-by":"publisher","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:eaaw1736.","journal-title":"Sci Transl Med"},{"key":"776_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase\u00a0II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81:815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"776_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3899\/jrheum.151290","volume":"43","author":"B Combe","year":"2016","unstructured":"Combe B, Behrens F, McHugh N, et al. Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol. 2016;43:1063\u20137.","journal-title":"J Rheumatol"},{"key":"776_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000181","volume":"1","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;1:e000181.","journal-title":"RMD Open"},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13075-020-02388-5","volume":"23","author":"B Combe","year":"2021","unstructured":"Combe B, Tsai TF, Huffstutter JE, et al. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week\u00a052 results from Spirit-P1 and Spirit-P2 studies. Arthritis Res Ther. 2021;23:41.","journal-title":"Arthritis Res Ther"},{"key":"776_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase\u00a0III trial. Arthritis Rheumatol. 2019;71:1112\u201324.","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00776-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T10:28:30Z","timestamp":1758364110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00776-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00776-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Atul Deodhar: Consulting and\/or advisory boards: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, UCB; Research grants: AbbVie, Bristol Myers Squibb, Celgene, MoonLake Immunotherapeutics, Lilly, Novartis, Pfizer, UCB. Miroslawa Nowak and Tom Lehman: Employees and shareholders: Bristol Myers Squibb. June Y. Ye and Subhashis Banerjee: Employees and shareholders: Bristol Myers Squibb at the time of the study; Currently affiliated with Artiva Biotherapeutics. Philip J. Meese: Research grants: AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, UCB; Consulting and\/or speaker fees: AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gal\u00e1pagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, UCB, Ventyx Biosciences, XinThera.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki of 1964, and its later amendments, the International Conference on Harmonisation Guidelines for Good Clinical practice and local regulations. An institutional review board or independent ethics committee at each site approved all study documents, including the protocol, consent form and any other written information provided to patients. All participants provided informed consent to participate in the study before taking part [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}